Matthew E Eagles1, Michael K Tso2, R Loch Macdonald3. 1. Section of Neurosurgery, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. Electronic address: matthew.eagles@ucalgary.ca. 2. Department of Neurosurgery, University at Buffalo Neurosurgery, Buffalo, New York, USA. 3. Department of Neurosurgery, University at Buffalo Neurosurgery, Buffalo, New York, USA; Division of Neurosurgery, St. Michael's Hospital, Toronto, Ontario, Canada; Labatt Family Centre of Excellence in Brain Injury and Trauma Research, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; Department of Physiology, University of Toronto, Toronto, Ontario, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Measures such as modified Rankin Scale (mRS) may not reflect cognitive outcome following aneurysmal subarachnoid hemorrhage. The aim of this study was to assess the relationship between functional outcome, measured by mRS, and cognition, measured by mini-mental state examination (MMSE), after aSAH. A secondary analysis evaluated the impact of delayed cerebral ischemia (DCI) on the proportion of patients who had cognitive impairment. METHODS: We performed a post hoc analysis of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial data. MMSE and mRS scores were compared using Kruskal-Wallis equality-of-populations rank test with pairwise comparison post hoc analysis. Cognitive impairment was defined as MMSE score <27. A stepwise logistic regression model evaluated whether DCI was a predictor of cognitive impairment. RESULTS: CONSCIOUS-1 comprised 413 patients. Of these, 337 took an MMSE at their 12-week follow-up. Mean MMSE score was 27 with a median of 29 (range, 0-30; SD 5.4). There were no significant differences between MMSE scores of patients who had 12-week mRS scores of 0-2. On multivariate analysis, DCI was independently associated with cognitive impairment after aSAH. CONCLUSIONS: Patients considered to have a good outcome on mRS had varying degrees of cognitive function on MMSE, whereas development of DCI was an independent predictor of cognitive impairment after aSAH. MMSE may not be sensitive enough to discern subtle defects in cognition, as the median score was 29 out of 30.
BACKGROUND: Measures such as modified Rankin Scale (mRS) may not reflect cognitive outcome following aneurysmal subarachnoid hemorrhage. The aim of this study was to assess the relationship between functional outcome, measured by mRS, and cognition, measured by mini-mental state examination (MMSE), after aSAH. A secondary analysis evaluated the impact of delayed cerebral ischemia (DCI) on the proportion of patients who had cognitive impairment. METHODS: We performed a post hoc analysis of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial data. MMSE and mRS scores were compared using Kruskal-Wallis equality-of-populations rank test with pairwise comparison post hoc analysis. Cognitive impairment was defined as MMSE score <27. A stepwise logistic regression model evaluated whether DCI was a predictor of cognitive impairment. RESULTS: CONSCIOUS-1 comprised 413 patients. Of these, 337 took an MMSE at their 12-week follow-up. Mean MMSE score was 27 with a median of 29 (range, 0-30; SD 5.4). There were no significant differences between MMSE scores of patients who had 12-week mRS scores of 0-2. On multivariate analysis, DCI was independently associated with cognitive impairment after aSAH. CONCLUSIONS:Patients considered to have a good outcome on mRS had varying degrees of cognitive function on MMSE, whereas development of DCI was an independent predictor of cognitive impairment after aSAH. MMSE may not be sensitive enough to discern subtle defects in cognition, as the median score was 29 out of 30.
Authors: M-A Labeyrie; S Gaugain; G Boulouis; A Zetchi; J Brami; J-P Saint-Maurice; V Civelli; S Froelich; E Houdart Journal: AJNR Am J Neuroradiol Date: 2019-07-18 Impact factor: 3.825
Authors: Michael Hugelshofer; Raphael M Buzzi; Christian A Schaer; Henning Richter; Kevin Akeret; Vania Anagnostakou; Leila Mahmoudi; Raphael Vaccani; Florence Vallelian; Jeremy W Deuel; Peter W Kronen; Zsolt Kulcsar; Luca Regli; Jin Hyen Baek; Ivan S Pires; Andre F Palmer; Matthias Dennler; Rok Humar; Paul W Buehler; Patrick R Kircher; Emanuela Keller; Dominik J Schaer Journal: J Clin Invest Date: 2019-12-02 Impact factor: 14.808
Authors: W Taylor Kimberly; Eric S Rosenthal; India A Lissak; Sahar F Zafar; M Brandon Westover; Riana L Schleicher; Jennifer A Kim; Thabele Leslie-Mazwi; Christopher J Stapleton; Aman B Patel Journal: Stroke Date: 2020-03-11 Impact factor: 7.914
Authors: Joseph R Geraghty; Melissa N Lara-Angulo; Milen Spegar; Jenna Reeh; Fernando D Testai Journal: J Stroke Cerebrovasc Dis Date: 2020-06-20 Impact factor: 2.136
Authors: Riana L Schleicher; Matthew B Bevers; Daniel B Rubin; Matthew J Koch; Søren Bache; India A Lissak; Aman B Patel; Eric S Rosenthal; Kirsten Møller; W Taylor Kimberly Journal: Stroke Date: 2021-06-25 Impact factor: 10.170
Authors: Ilari M Rautalin; Martina Sebök; Menno R Germans; Miikka Korja; Noemi Dannecker; Olivia Zindel-Geisseler; Peter Brugger; Luca Regli; Martin N Stienen Journal: Neurol Sci Date: 2019-12-04 Impact factor: 3.307